Abstract:Purpose/Objective(s)To update the outcomes with IMRT in the treatment of primary NPC and to analyzed the pattern of failure and prognostic factors.Materials/MethodsBetween February 2001 and December 2006, 419 patients with newly diagnosed nasopharyngeal carcinoma were treated with IMRT at the Sun Yat-sen University Cancer Center. There were 91 females and 328 males, with a median age of 43 (range, 13∼78). According to the UICC/AJCC2002 staging classification, 28 patients had stage I, 113 patients had stage II, 202 patients had stage III, and 76 patients had stage IV. 181 patients received radical radiotherapy alone while 238 patients received chemoradiotherapy. Targets and critical structures were defined as described in ICRU report#50. The prescribed doses were 66-70Gy/25-30f to the nasopharyngeal gross tumor volume (GTVnx) and 60-66Gy/25-30f to the positive lymph nodes (GTVnd), 55-62Gy/25-30f to the first clinical target volume (Target1), and 42-54Gy/25-30f to the second clinical target volume (Target2), The survival rate was calculated by Kaplan-Meier, COX multivariate prognosis analysis was performed.ResultsWith a median follow-up of 36 months (range, 6∼80 months), 74 patients failed after the treatment, 27.0% of them (20/74) failed in local or region alone, 66.2% (49/74) failed in distant metastases, 6.8% (5/74) developed distant metastases associated with local or regional recurrence. 47 patients have died, 74.5% (35/47) of them were for the reason of distant metastases. The 4-year estimated local-regional progression-free survival rate, distant metastases-free survival rate (DMFS), progression-free survival rate (PFS), disease-specific survival rate (DSS) was 91.9%,87.0% ,80.1% and 89.8%. In univariate analysis, the PFS, DMFS, and DSS of patients with early T stage, early N stage, gross tumor volume (GTVnx) ≤30cm3 are much higher than those with advanced T stage (p < 0.05), advanced N stage (p < 0.05), GTVnx>30cm3 (p < 0.05). In multivariate analysis, the N stage (p = 0.00) and GTVnx (p = 0.00)are independent prognostic factors for PFS, DMFS and DSS.ConclusionsThe outcomes with big amount of cases in our single institution have proved that intensity modulated radiotherapy can reduce the acute and late toxicities in the treatment of nasopharyngeal carcinoma, and obviously improve the local-regional control rate and survival rate. Distant metastases are now the dominant form of failure and death. For the patients with advanced N stage and large GTVnx, we need more research for much efficacious multimodality therapy strategy. Purpose/Objective(s)To update the outcomes with IMRT in the treatment of primary NPC and to analyzed the pattern of failure and prognostic factors. To update the outcomes with IMRT in the treatment of primary NPC and to analyzed the pattern of failure and prognostic factors. Materials/MethodsBetween February 2001 and December 2006, 419 patients with newly diagnosed nasopharyngeal carcinoma were treated with IMRT at the Sun Yat-sen University Cancer Center. There were 91 females and 328 males, with a median age of 43 (range, 13∼78). According to the UICC/AJCC2002 staging classification, 28 patients had stage I, 113 patients had stage II, 202 patients had stage III, and 76 patients had stage IV. 181 patients received radical radiotherapy alone while 238 patients received chemoradiotherapy. Targets and critical structures were defined as described in ICRU report#50. The prescribed doses were 66-70Gy/25-30f to the nasopharyngeal gross tumor volume (GTVnx) and 60-66Gy/25-30f to the positive lymph nodes (GTVnd), 55-62Gy/25-30f to the first clinical target volume (Target1), and 42-54Gy/25-30f to the second clinical target volume (Target2), The survival rate was calculated by Kaplan-Meier, COX multivariate prognosis analysis was performed. Between February 2001 and December 2006, 419 patients with newly diagnosed nasopharyngeal carcinoma were treated with IMRT at the Sun Yat-sen University Cancer Center. There were 91 females and 328 males, with a median age of 43 (range, 13∼78). According to the UICC/AJCC2002 staging classification, 28 patients had stage I, 113 patients had stage II, 202 patients had stage III, and 76 patients had stage IV. 181 patients received radical radiotherapy alone while 238 patients received chemoradiotherapy. Targets and critical structures were defined as described in ICRU report#50. The prescribed doses were 66-70Gy/25-30f to the nasopharyngeal gross tumor volume (GTVnx) and 60-66Gy/25-30f to the positive lymph nodes (GTVnd), 55-62Gy/25-30f to the first clinical target volume (Target1), and 42-54Gy/25-30f to the second clinical target volume (Target2), The survival rate was calculated by Kaplan-Meier, COX multivariate prognosis analysis was performed. ResultsWith a median follow-up of 36 months (range, 6∼80 months), 74 patients failed after the treatment, 27.0% of them (20/74) failed in local or region alone, 66.2% (49/74) failed in distant metastases, 6.8% (5/74) developed distant metastases associated with local or regional recurrence. 47 patients have died, 74.5% (35/47) of them were for the reason of distant metastases. The 4-year estimated local-regional progression-free survival rate, distant metastases-free survival rate (DMFS), progression-free survival rate (PFS), disease-specific survival rate (DSS) was 91.9%,87.0% ,80.1% and 89.8%. In univariate analysis, the PFS, DMFS, and DSS of patients with early T stage, early N stage, gross tumor volume (GTVnx) ≤30cm3 are much higher than those with advanced T stage (p < 0.05), advanced N stage (p < 0.05), GTVnx>30cm3 (p < 0.05). In multivariate analysis, the N stage (p = 0.00) and GTVnx (p = 0.00)are independent prognostic factors for PFS, DMFS and DSS. With a median follow-up of 36 months (range, 6∼80 months), 74 patients failed after the treatment, 27.0% of them (20/74) failed in local or region alone, 66.2% (49/74) failed in distant metastases, 6.8% (5/74) developed distant metastases associated with local or regional recurrence. 47 patients have died, 74.5% (35/47) of them were for the reason of distant metastases. The 4-year estimated local-regional progression-free survival rate, distant metastases-free survival rate (DMFS), progression-free survival rate (PFS), disease-specific survival rate (DSS) was 91.9%,87.0% ,80.1% and 89.8%. In univariate analysis, the PFS, DMFS, and DSS of patients with early T stage, early N stage, gross tumor volume (GTVnx) ≤30cm3 are much higher than those with advanced T stage (p < 0.05), advanced N stage (p < 0.05), GTVnx>30cm3 (p < 0.05). In multivariate analysis, the N stage (p = 0.00) and GTVnx (p = 0.00)are independent prognostic factors for PFS, DMFS and DSS. ConclusionsThe outcomes with big amount of cases in our single institution have proved that intensity modulated radiotherapy can reduce the acute and late toxicities in the treatment of nasopharyngeal carcinoma, and obviously improve the local-regional control rate and survival rate. Distant metastases are now the dominant form of failure and death. For the patients with advanced N stage and large GTVnx, we need more research for much efficacious multimodality therapy strategy. The outcomes with big amount of cases in our single institution have proved that intensity modulated radiotherapy can reduce the acute and late toxicities in the treatment of nasopharyngeal carcinoma, and obviously improve the local-regional control rate and survival rate. Distant metastases are now the dominant form of failure and death. For the patients with advanced N stage and large GTVnx, we need more research for much efficacious multimodality therapy strategy.

Abstract:Purpose/ObjectiveTo report the clinical outcome of 934 patients with primary nasopharyngeal carcinoma, treated with conventional external beam radiation therapy alone.Materials/Methods934 patients were treated in the Sun Yat-Sen University Cancer Center, from Jan. 1, 1999 to Dec. 31, 1999. All the patients had primary nasopharyngeal carcinoma, confirmed by histo-pathology, CT and/or MRI. They were staged using the 1992 Chinese FuZhou staging system for nasopharyngeal carcinoma. There were 35 stage I (3.7%), 215 stage II (23.0%), 488 stage III (52.2%) and 196 stage IV (21.0%) patients. The radiation therapy fields were delineated according to the CT/MRI imaging findings on disease extensions. Two lateral opposed isocentric portals with customized blocking were used for the nasopharynx and upper neck. The anterior lower neck field was separated and matched to the superior fields. Using cone-down technique, the nasopharynx received 70Gy. The spinal cord tolerance was respected with the two lateral opposed on cord portals irradiating to 36-40Gy. Conventional external beam radiation therapy was utilized. The tumor dose delivered to the nasopharynx was 69.7Gy ± 2.4Gy, given in daily fractions of 2Gy for 7–7.5 weeks. The boost dose 10Gy/5fractions was delivered when there was still residual diseases in the base skull or the parapharynx at the end of radiotherapeutic course. The delivered doses to the neck were 60-70Gy (positive lymph nodes) and 50Gy (negative lymph nodes) respectively. The boost dose 10Gy/5 fractions was delivered using electron beam when the residual lymph node of the neck was more than 10 mm at the end of radiotherapeutic course.ResultsThe median follow-up time was 40 months (range 1.4–56.1 months). The 1, 2, 3 and 4-year overall survival rates (OS), metastasis-free survival rates (MFS), disease-free survival rates (DFS) and relapse-free survival rates(RFS) were shown in the table 1. The 4-year overall survival rate for stages I, II, III and IV were 89.3%, 81.8%, 77.1% and 65.0% respectively. At the end of the radiotherapeutic course, the percentages for residual disease were 3.1% in the nasopharynx, 9.5% in the cervical lymph nodes, and 1.9% in both the nasopharynx and the cervical lymph nodes. The loco-regional recurrence rate and the distance metastasis rate were 7.2% and 9.2% respectively. The local recurrence percentages were approximately 6.4% for stages T1-T2 disease and 13.0% for stages T3-T4 disease; 1.0% for N0 patients and 7.6% for N1-N3 patients. The median time for the local regional recurrence and the distance metastases were 19.3 months and 12.8 months after radiotherapy.ConclusionsThere was a 10% improvement in the 2, 3 and 4-year overall survival rates when compared to the results of the past 20 years. The possible reasons for the significant improvement may be (1) the target volumes for radiotherapy were delineated according to CT/MRI imaging, and (2) the change from split-course to continuous radiotherapy and thus shorter overall treatment duration. Both factors have contributed to the improved local control leading to survival benefits. However, the survival rates for the patients with locally-advanced disease are still low. It is recommended that patients with locally-advanced disease should be treated with combined radiotherapy and chemotherapy. Purpose/ObjectiveTo report the clinical outcome of 934 patients with primary nasopharyngeal carcinoma, treated with conventional external beam radiation therapy alone. To report the clinical outcome of 934 patients with primary nasopharyngeal carcinoma, treated with conventional external beam radiation therapy alone. Materials/Methods934 patients were treated in the Sun Yat-Sen University Cancer Center, from Jan. 1, 1999 to Dec. 31, 1999. All the patients had primary nasopharyngeal carcinoma, confirmed by histo-pathology, CT and/or MRI. They were staged using the 1992 Chinese FuZhou staging system for nasopharyngeal carcinoma. There were 35 stage I (3.7%), 215 stage II (23.0%), 488 stage III (52.2%) and 196 stage IV (21.0%) patients. The radiation therapy fields were delineated according to the CT/MRI imaging findings on disease extensions. Two lateral opposed isocentric portals with customized blocking were used for the nasopharynx and upper neck. The anterior lower neck field was separated and matched to the superior fields. Using cone-down technique, the nasopharynx received 70Gy. The spinal cord tolerance was respected with the two lateral opposed on cord portals irradiating to 36-40Gy. Conventional external beam radiation therapy was utilized. The tumor dose delivered to the nasopharynx was 69.7Gy ± 2.4Gy, given in daily fractions of 2Gy for 7–7.5 weeks. The boost dose 10Gy/5fractions was delivered when there was still residual diseases in the base skull or the parapharynx at the end of radiotherapeutic course. The delivered doses to the neck were 60-70Gy (positive lymph nodes) and 50Gy (negative lymph nodes) respectively. The boost dose 10Gy/5 fractions was delivered using electron beam when the residual lymph node of the neck was more than 10 mm at the end of radiotherapeutic course. 934 patients were treated in the Sun Yat-Sen University Cancer Center, from Jan. 1, 1999 to Dec. 31, 1999. All the patients had primary nasopharyngeal carcinoma, confirmed by histo-pathology, CT and/or MRI. They were staged using the 1992 Chinese FuZhou staging system for nasopharyngeal carcinoma. There were 35 stage I (3.7%), 215 stage II (23.0%), 488 stage III (52.2%) and 196 stage IV (21.0%) patients. The radiation therapy fields were delineated according to the CT/MRI imaging findings on disease extensions. Two lateral opposed isocentric portals with customized blocking were used for the nasopharynx and upper neck. The anterior lower neck field was separated and matched to the superior fields. Using cone-down technique, the nasopharynx received 70Gy. The spinal cord tolerance was respected with the two lateral opposed on cord portals irradiating to 36-40Gy. Conventional external beam radiation therapy was utilized. The tumor dose delivered to the nasopharynx was 69.7Gy ± 2.4Gy, given in daily fractions of 2Gy for 7–7.5 weeks. The boost dose 10Gy/5fractions was delivered when there was still residual diseases in the base skull or the parapharynx at the end of radiotherapeutic course. The delivered doses to the neck were 60-70Gy (positive lymph nodes) and 50Gy (negative lymph nodes) respectively. The boost dose 10Gy/5 fractions was delivered using electron beam when the residual lymph node of the neck was more than 10 mm at the end of radiotherapeutic course. ResultsThe median follow-up time was 40 months (range 1.4–56.1 months). The 1, 2, 3 and 4-year overall survival rates (OS), metastasis-free survival rates (MFS), disease-free survival rates (DFS) and relapse-free survival rates(RFS) were shown in the table 1. The 4-year overall survival rate for stages I, II, III and IV were 89.3%, 81.8%, 77.1% and 65.0% respectively. At the end of the radiotherapeutic course, the percentages for residual disease were 3.1% in the nasopharynx, 9.5% in the cervical lymph nodes, and 1.9% in both the nasopharynx and the cervical lymph nodes. The loco-regional recurrence rate and the distance metastasis rate were 7.2% and 9.2% respectively. The local recurrence percentages were approximately 6.4% for stages T1-T2 disease and 13.0% for stages T3-T4 disease; 1.0% for N0 patients and 7.6% for N1-N3 patients. The median time for the local regional recurrence and the distance metastases were 19.3 months and 12.8 months after radiotherapy. The median follow-up time was 40 months (range 1.4–56.1 months). The 1, 2, 3 and 4-year overall survival rates (OS), metastasis-free survival rates (MFS), disease-free survival rates (DFS) and relapse-free survival rates(RFS) were shown in the table 1. The 4-year overall survival rate for stages I, II, III and IV were 89.3%, 81.8%, 77.1% and 65.0% respectively. At the end of the radiotherapeutic course, the percentages for residual disease were 3.1% in the nasopharynx, 9.5% in the cervical lymph nodes, and 1.9% in both the nasopharynx and the cervical lymph nodes. The loco-regional recurrence rate and the distance metastasis rate were 7.2% and 9.2% respectively. The local recurrence percentages were approximately 6.4% for stages T1-T2 disease and 13.0% for stages T3-T4 disease; 1.0% for N0 patients and 7.6% for N1-N3 patients. The median time for the local regional recurrence and the distance metastases were 19.3 months and 12.8 months after radiotherapy. ConclusionsThere was a 10% improvement in the 2, 3 and 4-year overall survival rates when compared to the results of the past 20 years. The possible reasons for the significant improvement may be (1) the target volumes for radiotherapy were delineated according to CT/MRI imaging, and (2) the change from split-course to continuous radiotherapy and thus shorter overall treatment duration. Both factors have contributed to the improved local control leading to survival benefits. However, the survival rates for the patients with locally-advanced disease are still low. It is recommended that patients with locally-advanced disease should be treated with combined radiotherapy and chemotherapy. There was a 10% improvement in the 2, 3 and 4-year overall survival rates when compared to the results of the past 20 years. The possible reasons for the significant improvement may be (1) the target volumes for radiotherapy were delineated according to CT/MRI imaging, and (2) the change from split-course to continuous radiotherapy and thus shorter overall treatment duration. Both factors have contributed to the improved local control leading to survival benefits. However, the survival rates for the patients with locally-advanced disease are still low. It is recommended that patients with locally-advanced disease should be treated with combined radiotherapy and chemotherapy.

Pattern Of Failure And Prognostic Factors For Primary Nasopharyngeal Carcinoma (Npc) Treated With Intensity Modulated Radiotherapy (Imrt)

Long-term Outcome and Prognostic Factors of Patients with Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiation Therapy

Clinical Outcomes and Prognostic Factors of 582 Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiotherapy.

Long-term Effect and Prognostic Factors of 582 Nasopharyngeal Carcinoma Patients Treated with Intensity Modulated Radiotherapy

Clinical Study of the Necessity of Multiple Replanning During the Course of Intensity Modulated Radiation Therapy for Patients With Locally Advanced Nasopharyngeal Carcinoma

Retrospective Analysis Of 934 Primary Nasopharyngeal Carcinoma (Npc) Patients Treated With Conventional External Beam Radiotherapy Alone

Prognosis Analyses of 133 Nasopharyneal Carcinona from Northwest China Treated by Intensitymodulated Radiotherapy

Clinical Outcomes and Prognostic Factors of 695 Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiotherapy.

Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions

Long-term Survival Outcome and Failure Pattern after Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma

Preliminary Results of Intensity Modulated Radiation Therapy Alone for 122 Patients with Untreated Nasopharyngeal Carcinoma

Long-term Outcomes of Nasopharyngeal Carcinoma Patients with T1-2 Stage in Intensity-Modulated Radiotherapy Era.

Long-term outcomes of patients with advanced N-stage nasopharyngeal carcinoma treated by intensity-modulated radiotherapy alone or with chemotherapy

Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.

Selective Nodal Irradiation by Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma Aiming to Reduce Dysphagia and Xerostomia

Failure Patterns and Prognostic Factors for Cervical Node-Negative Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era.

Long-term Results and Prognostic Factors in 582 Nasopharyngeal Carcinoma Treated by Intensitymodulated Radiotherapy

Concurrent Chemotherapy Can Further Improve Clinical Outcome For Stage Iii Nasopharyngeal Carcinoma Patients Treated With Imrt In Endemic Area

Long-Term Outcomes of Intensity-Modulated Radiotherapy for 868 Patients with Nasopharyngeal Carcinoma: an Analysis of Survival and Treatment Toxicities

Preliminary Results of Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy: a Retrospective Study of 364 Patients

Clinical Outcome and Prognostic Factors of Intensity-Modulated Radiotherapy for T4 Stage Nasopharyngeal Carcinoma